These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3190562)

  • 1. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M; Arigliani R; Molinari AC; Tarantino V
    Pediatr Med Chir; 1986; 8(5):703-5. PubMed ID: 3601700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Barratt PS; Toogood IR
    Med J Aust; 1987 Aug; 147(4):177-9. PubMed ID: 3657630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can deferoxamine be considered an ototoxic drug?
    Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
    Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ototoxicity of deferoxamine mesylate.
    Kanno H; Yamanobe S; Rybak LP
    Am J Otolaryngol; 1995; 16(3):148-52. PubMed ID: 7661308
    [No Abstract]   [Full Text] [Related]  

  • 10. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Schindléry C
    Med J Aust; 1988 Jun; 148(12):662-3. PubMed ID: 3380052
    [No Abstract]   [Full Text] [Related]  

  • 12. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
    Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U; Dondè E; Piatti G; Cappellini MD
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auditory involvement in thalassemia major.
    De Virgiliis S; Argiolu F; Sanna G; Cornacchia G; Cossu P; Cao A; Mallardi V; Puxeddu P
    Acta Haematol; 1979; 61(4):209-15. PubMed ID: 108901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vision and hearing during deferoxamine therapy.
    Cohen A; Martin M; Mizanin J; Konkle DF; Schwartz E
    J Pediatr; 1990 Aug; 117(2 Pt 1):326-30. PubMed ID: 2380834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cochlear implant in Thalassemia patient - Case report.
    Kataria T; Grover M; Sharma S; Samdani S; Sharma MP
    Cochlear Implants Int; 2019 Jan; 20(1):47-50. PubMed ID: 30232935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
    Triantafyllou N; Fisfis M; Sideris G; Triantafyllou D; Rombos A; Vrettou H; Mantouvalos V; Politi C; Malliara S; Papageorgiou C
    Acta Neurol Scand; 1991 May; 83(5):306-8. PubMed ID: 1648295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hearing impairment during deferoxamine therapy for thalassemia major.
    Argiolu F; Diana G; Avignone A; Cao A; Di Ninni S
    J Pediatr; 1991 May; 118(5):826-7. PubMed ID: 2019945
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.